The Board of Directors of Vineet Laboratories Limited approved a rights issue to raise up to Rs. 30 crore by issuing equity shares with a face value of Rs. 10 each to eligible shareholders. This decision was made in the board meeting held on November 27, 2025. The issue is subject to regulatory approvals and the detailed terms will be communicated in a Letter of Offer to shareholders in due course. A Rights Issue Committee has been formed to oversee the process.

Vineet Laboratories Limited operates in the pharmaceutical sector, specializing in drug intermediates and bulk drugs. The company manufactures active pharmaceutical ingredients (API) intermediates and fine chemicals. It caters to domestic and international markets with products including Lopinavir, Ritonavir, Efavirenz, Nadolol, and Celecoxib among others. The company is noted for its manufacturing capabilities and serves multiple multinational pharmaceutical clients.

Financially, Vineet Laboratories has faced challenges recently. For the quarter ended September 2025, the company reported revenue but no detailed profit figures were mentioned in the notice. Previous quarters have shown fluctuations with reported revenue of Rs. 17.43 crore for Q2 FY2026, with significant drops and recoveries observed compared to prior quarters and previous years. The company has not disclosed prominent investors publicly; however, promoter Gaddam Venkata Ramana holds a notable stake.

The rights issue aims to strengthen the company’s capital for future growth and operational needs. As per recent market data and news, Vineet Laboratories is preparing to stabilize its financials and expand through this capital infusion.